11/17/2026 | Press release | Distributed by Public on 11/17/2026 21:20
WASHINGTON - Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) today chaired a hearing to examine the high cost of prescription drugs and proposed legislative solutions. Last year, the Judiciary Committee advanced six Grassley-backed, bipartisan bills to lower prescription drug prices through competition transparency and to address anticompetitive tactics in the pharmaceutical supply chain. One of those bills, the Affordable Prescriptions for Patients Act, passed the Senate unanimously in July. The remaining bills have not received a vote on the Senate floor.
Today's witnesses urged Congress to pass bipartisan legislation and echoed Grassley's calls for the Federal Trade Commission (FTC) to complete its 6(b) study of pharmacy benefit managers (PBMs). The witnesses also detailed how PBMs increase the cost of prescription drugs and outlined mechanisms to hold PBMs accountable.
Grassley questioned the following witnesses:
Video and excerpts of Grassley's questions follow. Read Grassley's opening statement HERE.
On the FTC's Final PBM Report:
GRASSLEY: "It's been four years since the FTC began their study of PBMs. Patients, rural pharmacies and Congress are still waiting for the study and its recommendations. Dr. Pitlick, how is the delay of the FTC's final report on PBMs impacting patients and rural pharmacies? Why is getting this report so important?"
PITLICK: "The interim reports are non-binding, but they gave great information and great insight. Like you said in your opening statement, we are waiting for the full report with legislative action that Congress can take. I think that Congress is deserving of that, the public is deserving of that, and taxpayers deserve it as well."
On the impact of Grassley-backed, bipartisan drug pricing bills:
GRASSLEY: "Ms. Basey, last year, this committee took a comprehensive [approach] to reducing drug costs… These bills will bring cheaper treatment faster to the market and hold drug companies and PBMs accountable. The Senate has now passed just one of these six competition bills. So, for you, what impact would these remaining five bills have on patients, and why should the Senate act now?"
BASEY: "Lower cost competition is essential for the one in three Americans who are struggling to afford their prescription drug prices. These bills, if passed together, would help close some of the loopholes in the patent and regulatory systems that the pharmaceutical industry uses to abuse the system and keep prices high at the expense of American patients…
"We need lower cost drugs sooner, so that patients can benefit and so that taxpayers can benefit too. These bills would all save money, and they would make a difference for millions of patients around the country."
On PBMs driving up the prices of prescription drugs:
GRASSLEY: "Dr. Oshmyansky, according to a recent study, Part D Medicare could save as much as $8.6 billion dollars annually if it were using the same pricing for certain generic drugs as the Cost Plus Drug Company uses. In other words, you're getting a better deal for patients, while under the Part D program, PBMs drive up the cost for seniors and taxpayers.
"So, how does the Cost Plus Drug Company achieve these lower prices, and what barriers does a company face when entering or expanding in the prescription drug market?"
OSHMYANSKY: "We try to go back to the 1850s in terms of our pricing model. You can go to our website, and you can see what it is exactly we pay for the drugs… we add a 15% margin as our markup, a $5 fee to pay our pharmacist, a $5 shipping and handling [fee], and that's the total cost of the medication. Everything else - that entire $8.6 billion difference - that's just intermediaries in the supply chain, adding their markup...
"You might get asked to pay a $3,000 copayment for Imatinib for Chronic Myelogenous Leukemia. From us, [the] exact same drug [from the] exact same drug company [would be] about $30... The one thing we cannot do at the moment is get access to the branded, patented and specialty drug products. If we could break through that, I think we could drive down drug costs for the country much further."
On the positive impact of establishing fiduciary responsibilities on PBMs:
GRASSLEY: "I'm glad the Department of Labor recently implemented PBM reform for some employer-sponsored health plans. Under federal rules for employer-sponsored health plans, there's a question as to whether PBMs have a fiduciary responsibility to health plan sponsors. PBMs would argue that they're getting the best deal for their clients. PBMs' opaqueness and tactics made me question that position. I'm all in for regulating PBMs, but we ultimately need a comprehensive mechanism to hold these PBMs accountable. Otherwise, we're playing whack-a-mole with PBM behavior.
"You talked about this in your 2025 testimony before this committee. So, why would establishing an explicit fiduciary duty standard, given the recent Department of Labor recommendation, help ensure PBMs have a duty to work for the benefit of the consumer?
SOOD: "What the new laws do, the Department of Labor regulations and the [Consolidated Appropriations Act of 2026], is they ask PBMs to disclose to employers how they are making money and their contracts with pharmacies. But disclosure is not enough to change their practices. As Dr. Alex said, there's only three PBMs, and if every PBM is doing the same games, switching PBMs is not going to help.
"What you need is accountability ultimately to plan members. As the [PBM] FAIR Act does, it gives fiduciary responsibility to PBMs. That fiduciary responsibility is owed to employees and plan members. So, even if employers don't act under [the Employee Retirement Income Security Act (ERISA)], the Department of Labor or employees could act and hold PBMs accountable. If PBMs say they're doing a great job for our patients, be [held] accountable for it - that's what fiduciary responsibility does."
-30-